Surgery Partners rejects Bain Capital's take-private offer

Surgery Partners (SGRY) rejected Bain Capital's take-private offer of $25.75 per share, citing an inability to agree on terms; Bain Capital already holds a 38.97% stake in the company. Following the announcement, Surgery Partners' shares fell over 13% to $20.10 in premarket trading. The company plans to host an investor day in the second half of 2025 and reiterated its annual revenue forecast of $3.3 billion to $3.45 billion, aligning with analysts' estimates.

Analysis

Surgery Partners (SGRY.O) has rejected a take-private offer from its largest shareholder, Bain Capital, which holds a 38.97% stake, citing an inability to agree on terms after Bain's January offer of $25.75 per share. This decision, made by a special committee of independent directors opting to continue as a publicly traded entity, triggered a significant negative market reaction, with Surgery Partners' shares declining over 13% to $20.10 in premarket trading, well below the offer price. Despite the failed acquisition, the company reiterated its annual revenue forecast of $3.3 billion to $3.45 billion, aligning with the analysts' average estimate of $3.38 billion, and plans to detail its strategy and outlook during an investor day in the second half of 2025. The situation is contextualized by previous, albeit unconsummated, acquisition interest from private equity firm TPG and healthcare giant UnitedHealth Group, noted in a Bloomberg News report referenced as being from August 2024, suggesting underlying strategic value even as this specific deal unravels.

Key Decisions for Investors

• Investors should anticipate continued share price volatility for Surgery Partners, with the current price of $20.10 reflecting the removal of the acquisition premium previously associated with Bain Capital's $25.75 per share offer.
• Carefully monitor the company's performance against its reiterated annual revenue forecast of $3.3 billion to $3.45 billion and look for strategic clarity at the planned investor day in the second half of 2025.
• Re-evaluate Surgery Partners' valuation based on its standalone prospects, considering the board's commitment to public status and the unresolved dynamic of Bain Capital's significant 38.97% holding, while noting that past M&A interest from other entities could resurface.